BMS Just Paid to Solve Its Patent Cliff With Someone Else’s Pipeline

Picture the scene inside BMS’s business development group sometime in late 2025: a spreadsheet mapping the company’s oncology and hematology portfolio against its patent expiry timeline, and a yawning gap where peak sales should be. Revlimid’s loss of exclusivity had already carved billions from the top line. Opdivo, the franchise cornerstone, faced intensifying checkpoint competition from AstraZeneca’s Imfinzi, Merck’s Keytruda, and a growing field of next-generation PD-(L)1 combinations. The internal pipeline, measured against the capital required to fill that gap organically, kept producing the same uncomfortable answer. So the BD team went hunting — and the trail led to Shanghai.

The result is a strategic multi-program collaboration between Hengrui Pharma and Bristol Myers Squibb spanning oncology, hematology, and immunology — 13 programs in total. That number alone deserves a pause. Most landmark licensing deals in biopharma involve one or two assets, occasionally three. Thirteen programs means BMS did not license a drug. It licensed a research organization.

The mechanics of the deal structure — upfront payments, development milestones, royalty tiers — follow the conventional architecture of a multinational licensing agreement. But the scale and the breadth mark a categorical shift in how a top-five Western pharma company is thinking about its next decade of growth. BMS effectively acknowledged that Hengrui’s pipeline, built on more than ten novel antibody-drug conjugate molecules and 26 independently developed innovative candidates across oncology and immunology as of Hengrui’s 2024 annual report, represents something the company could not afford to build on its own timeline.

The Pipeline Gap BMS Stopped Pretending Doesn’t Exist

The strategic logic becomes sharper when you map BMS’s portfolio pressure against the global oncology market, which Precedence Research sized at $225 billion in 2024 and projects will reach $668 billion by 2034 at an 11.5% CAGR. A market growing that fast punishes companies that stand still. And BMS, for all its legacy strength in immuno-oncology, has been standing closer to still than its investor presentations suggest.

Opdivo’s trajectory illustrates the problem precisely. The drug generated extraordinary returns through 2021, but its commercial profile has been compressed by Keytruda’s dominance in frontline settings and by an increasingly crowded competitive environment across NSCLC, RCC, and melanoma. BMS responded with the $13 billion acquisition of Mirati Therapeutics — closed in early 2024 — for KRAS G12C inhibitor adagrasib. It responded with the $4.1 billion acquisition of Karuna Therapeutics for the CNS asset KarXT. These are good assets in targeted markets. They do not constitute a rebuilt oncology franchise at the scale BMS needs.

Hengrui changes the math. The company’s track record in oncology is not theoretical: camrelizumab, its anti-PD-1 antibody, combined with apatinib (rivoceranib, a VEGFR-2 inhibitor), generated Phase 3 data supporting first-line approval in China for unresectable or metastatic hepatocellular carcinoma. The combination subsequently earned an FDA approval — a regulatory validation that Chinese-originated science can clear the agency’s highest bar. Hengrui’s ADC portfolio, with more than ten novel molecules in development, sits directly in the most commercially competitive and scientifically productive modality in oncology right now, where Pfizer paid $43 billion for Seagen precisely because the field concluded that ADC was the next platform technology.

BMS, by signing 13 programs instead of cherry-picking two or three, is treating Hengrui’s pipeline the way a private equity firm treats a platform acquisition — buy the factory, not just the product.

What Everyone Gets Wrong About China-to-West Licensing

The conventional narrative frames these deals as China catching up: a domestic innovator gaining Western validation and a path to global markets by attaching itself to a multinational’s regulatory infrastructure and commercial engine. Under that framing, BMS is doing Hengrui a favor. Sit with that assumption for thirty seconds, then look at the actual leverage dynamics.

Hengrui had options. The company, which reported record-high revenue in 2024 according to its annual results, is not a cash-constrained startup desperate for a partner’s balance sheet. Its ADC pipeline and immuno-oncology portfolio were generating interest from every major Western pharma with a portfolio gap — which, at this stage of the patent cliff cycle, means nearly all of them. AstraZeneca has spent aggressively in China-originated oncology assets. Pfizer, post-Seagen integration, has openly signaled interest in external ADC programs. Merck’s BD team has been active across Asia-Pacific partnerships for two years. Hengrui, in other words, was sitting in the middle of a competitive auction. BMS needed to offer something beyond a check.

What BMS brought was commercial scale in markets where Hengrui has not yet built a launch infrastructure — the U.S., Europe, and Japan — combined with regulatory expertise accumulated across decades of oncology submissions. That combination creates a genuine partnership rather than a simple cash transaction. But the dynamic has shifted far enough that calling this “Western pharma rescuing a Chinese innovator” misreads who needs whom.

The FDA approval trajectory for Chinese-originated compounds reinforces the point. Sunshine Lake Pharma received FDA approval on May 4, 2026 for Langlara, its long-acting insulin — becoming the fourth insulin glargine product to clear the agency and the first from a Chinese manufacturer. The regulatory wall that once made Western pharma the mandatory gateway to the U.S. market is eroding, submission by submission. Companies like Hengrui are watching that precedent carefully. Every Chinese approval at FDA reduces the leverage that Western partners once held unconditionally.

What the BMS-Hengrui Architecture Signals to the Rest of the Field

Thirteen programs create a different kind of strategic relationship than a single-asset license. When one program fails — and in a portfolio of thirteen, several will — neither party has an incentive to walk away from the relationship. The partnership becomes self-reinforcing in a way that bilateral single-asset deals never are. BMS’s existing partnership infrastructure already demonstrates the company’s comfort with complex, long-duration relationships; its $380 million capacity reservation agreement with Cellares for CAR T manufacturing is a separate example of BMS thinking in platforms rather than transactions. The Hengrui deal extends that logic into early-to-mid stage pipeline development at a scale the company has not previously attempted with an Asian innovator.

The BD teams at AbbVie, Pfizer, and Roche should be running the same spreadsheet BMS ran. Each faces its own version of the patent cliff math: AbbVie’s Humira biosimilar erosion, Roche’s Herceptin and Rituxan losses already absorbed but with the next generation of oncology assets still maturing, Pfizer’s post-Seagen integration pressure to justify a $43 billion valuation. The pool of Western late-stage oncology assets available for licensing at reasonable multiples has thinned dramatically over the past three years, while the quality and depth of Chinese pipeline science has moved in exactly the opposite direction. Hengrui’s 26 clinical-stage molecules and ten-plus ADC programs represent a supply of innovation that the Western market cannot replicate on equivalent timelines or at equivalent cost.

Any BD team that frames Chinese pharma partnerships purely as geographic expansion — gaining access to the China market — is solving the wrong problem. The more urgent opportunity is importing pipeline velocity into a Western portfolio that has been running on a combination of legacy assets and increasingly expensive M&A. The question is not whether to engage Chinese innovators. The question is which ones are worth 13-program scale, and whether your company still has the negotiating position to get there before Hengrui’s next partner conversation makes the price significantly less attractive.

Back in that BMS conference room, the spreadsheet that started this whole exercise now has a different problem on the right side of the ledger: thirteen new programs to diligence, develop, and sequence toward launch. That is an execution burden as real as the portfolio gap it was designed to solve. But it is, unambiguously, a better problem to have — and every competitor still staring at the original spreadsheet knows it.

References

1. PR Newswire — “Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology”
2. Moomoo News — “In 2024, Jiangsu Hengrui Pharmaceuticals Achieved Record-High Revenue” (Hengrui 2024 Annual Report pipeline data)
3. Bristol Myers Squibb — “Our Partnerships” (Cellares $380M CAR T capacity reservation agreement)
4. Precedence Research — “Oncology Market Size, Share and Trends 2025–2034”
5. CGTN — “Chinese insulin breaks into US market as new drug secures FDA approval” (Sunshine Lake Pharma Langlara, May 4, 2026)
6. Hengrui Pharma — 2024 Annual Report (camrelizumab + apatinib Phase 3 HCC data and regulatory approvals)